Back

Clinical outcomes of beta-blocker therapy after myocardial infarction in patients with preserved or mildly reduced ejection fraction

10 May 2026 (16:30 - 17:00)
Organised by: Logo
Congress Presentation Part of: Integrated and multidisciplinary care strategies to prevent remodelling in heart failure Beta-Blockers Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Bernardo Lisboa Resende

Coimbra Hospital and University Center, Coimbra (Portugal)

4 More presentations in this session

Presentation thumbnail
Impact of early initiation of sodium-glucose cotransporter 2 inhibitors on cardiac remodeling in patients with acute myocardial infarction: a meta-analysis and trial sequential analysis of controlled
Associate Professor D. D'Amario (Novara, IT)
Abstract Slides Video
Presentation thumbnail
Real-world outcomes and predictors of LV reverse remodelling after successful CTO PCI in HFrEF: insights from a multicentre registry
Assistant Professor J. Park (Busan, KR)
Abstract Slides Video
Presentation thumbnail
Impact of heart failure etiology after CRT upgrade
Associate Professor A. Kosztin (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
PCSK9 inhibition and cardiovascular outcomes by heart failure status: a pooled analysis of SPIRE-1 and SPIRE-2
Mr A. Razaghizad (Montreal, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Integrated and multidisciplinary care strategies to prevent remodelling in heart failure

The Event

Event poster

Heart Failure 2026

10 May 2026 16:30 CET
You may be interested in
thumbnail
Congress Presentation
Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
thumbnail
Congress Presentation
Betablockers post-acute myocardial infarction
thumbnail
Congress Presentation
Impact of beta-blocker therapy in patients with preserved left ventricular ejection fraction after ST-segment elevation myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources